Stock Forecast

  Pear Therapeutics, Inc. ( PEAR) Stock. Should you Buy or Sell?    $ 1.94

0.24 (11.01 %)

Pear Therapeutics, Inc. Analysis

Updated on 10-09-2022
Symbol PEAR
Price $1.94
Beta 0.000
Volume Avg. $271.24 thousand
Market Cap $269.21 M
52 Week Range $1.34 - $14.6

Pear Therapeutics, Inc. opened the day at $1.94 which is +'11.01 % on yesterday's close. Pear Therapeutics, Inc. has a 52 week high of $14.6 and 52 week low of $1.34, which is a difference of $13.26. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $269.21 M and total net profit is $4208000 which means the company is trading at 63.98 times profit to market capitalization. Theoretically, if you were to buy Pear Therapeutics, Inc. for $269.21 M, it would take 15 years to get your money back. Pear Therapeutics, Inc. are in the Health Information Services space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


Pear Therapeutics, Inc. Stock Forecast - Is Pear Therapeutics, Inc. a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreNeutral
ROA ScoreNeutral
DE ScoreBuy
PE ScoreStrong Buy
PB ScoreStrong Buy
Overall RecommendationStrong Buy

Growth and Value

PE Ratio -3.211
Dividend Yiel 0.000
Net Profit Margin -8.147

Valuing Pear Therapeutics, Inc.

Price Book Value Ratio 3.394 Price To Book Ratio 3.394
Price To Sales Ratio 26.163 Price Earnings Ratio -3.211

How liquid is Pear Therapeutics, Inc.

Current Ratio 2.574
Quick Ratio 2.395


Debt Ratio 0.445 Debt Equity Ratio 0.803
Long Term Debt To Capitalization 0.104 Total Debt To Capitalization 0.123

Latest news about Pear Therapeutics, Inc.

Pear Therapeutics Lays Off 9% Of Workforce, Guides For $15 Million Revenue

Lots of payors are adding reSET to their covered benefit plans, and savings results far exceed prices of the products, usually leaving about 50% in surplus for the health system. Payor contract economics is making timing issues for revenue recognition, but run-rate revenue still indicates Pear is still annualising $12 million in revenue.

Date : 18/08/2022

Pear Therapeutics, Inc. (PEAR) CEO Corey McCann on Q2 2022 Results - Earnings Call Transcript

Pear Therapeutics, Inc. (NASDAQ:PEAR ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Meara Murphy - Senior Director of Corporate Communications Ronan O'Brien - General Counsel and Chief Compliance Officer Corey McCann - President and Chief Executive Officer Chris Guiffre - Chief Financial Officer and Chief Operating Officer Yuri Maricich - Chief Medical Officer Julia Strandberg - Chief Commercial Officer Conference Call Participants Judah Frommer - Credit Suisse Michael Cherny - Bank of America Neena Garg - Citi Eric Percher - Nephron Research Rahul Rakhit - LifeSci Capital Keay Nakae - Chardan Marie Thibault - BTIG Operator Good afternoon, everyone. Welcome to the Pear Therapeutics Second Quarter 2022 Earnings Conference Call.

Date : 14/08/2022

Why Earnings Season Could Be Great for Pear Therapeutics (PEAR)

Pear Therapeutics (PEAR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Date : 10/08/2022

Penny Stocks To Buy Now? 3 With Unusual Options Activity To Watch

Penny stocks with unusual options activity today. The post Penny Stocks To Buy Now?

Date : 24/05/2022

Pear Therapeutics Sees Growing Fulfillment Rates And Payor Traction

Fulfilment rates are growing relative to last quarter, and so are prescriptions. Government traction is becoming more evident as states mandate coverage of Pear products for all resident Medicaid members, and payment rates should rise on account of that.

Date : 21/05/2022

About Pear Therapeutics, Inc.

Sector : Healthcare
Industry : Health Information Services

Website :

Exchange : NASDAQ Capital Market

Description :

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.

My Newsletter

Sign Up For Updates & Newsletters